Trial Profile
A Phase 2 Multi-Ascending Dose Trial to Assess the Efficacy, Tolerability and Pharmacokinetic Profile of Exendin (9-39) in Patients With Post-bariatric Hyperinsulinemic Hypoglycemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Aug 2020
Price :
$35
*
At a glance
- Drugs Avexitide (Primary)
- Indications Hypoglycaemia
- Focus Therapeutic Use
- Sponsors Eiger BioPharmaceuticals
- 29 Jun 2018 Status changed from active, no longer recruiting to completed.
- 12 Jun 2017 According to an Eiger BioPharmaceuticals media release, results (n=19) from this trial were presented at the 2017 American Diabetes Association meeting.
- 12 Jun 2017 Results published in an Eiger BioPharmaceuticals Media Release